Higher Survival is tied to Care at High-Volume Radiation Treatment Centers
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 16, 2023 -- Among men with very high-risk prostate cancer, higher radiation facility case volume is independently associated with longer overall survival, according to a study published online Aug. 8 in JAMA Network Open.
Nikhil Sebastian, M.D., from Emory University in Atlanta, and colleagues examined differences in outcomes between patients with very high-risk prostate cancer treated at radiation facilities with high versus low patient volume. The analysis included 25,219 men identified from the National Cancer Database.
The researchers found that 25.5 percent of men were treated at facilities with high average cumulative volume. During a median of 57.4 months of follow-up, median overall survival was 123.4 months for men treated at high-volume centers versus 109.0 months for those treated at low-volume centers. Further, treatment at a high-volume center was associated with a lower risk for death (hazard ratio, 0.89). Results remained significant after inverse probability score weight-based adjustment.
"These findings suggest that the expertise and resources that accompany high-volume treatment facilities are associated with improved outcomes for men with very high-risk prostate cancer, but further investigation is needed to identify the specific causes for this association," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...
First-Line Biparametric MRI Less Cost-Effective Than PSA for Prostate Cancer Screening
MONDAY, June 3, 2024 -- From an economic perspective, first-line prostate-specific antigen (PSA) testing is favored over biparametric magnetic resonance imaging (bpMRI) for...
Active Surveillance Effective Strategy for Favorable-Risk Prostate Cancer
FRIDAY, May 31, 2024 -- Active surveillance is an effective management strategy for men with favorable-risk prostate cancer, with an estimated rate of metastasis of 1.4 percent at...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.